ETFIQData as of Nov 19, 2026. · etfiq.com/funds/pbe

PBE Fact Sheet: Invesco Biotechnology & Genome ETF

Share
$92.59
close, Nov 20, 2026

Over the year to Nov 19, 2026, PBE returned +22.8% in total and charged 0.59% a year.

1-year total return
+20.1%
to Nov 20, 2026
Expense ratio
0.59%
a year
Net assets
$418m
on Nov 19, 2026
Net flow, last 5 trading days
+$24k
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

PBE $12,280 +22.8% · IVV $10,925 +9.2% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−7.0%
3 months−5.1%
Year to date+13.9%
1 year+20.1%
3 years+68.0%
5 years+29.0%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Biogen Inc5.86%
Gilead Sciences Inc5.86%
Regeneron Pharmaceuticals Inc5.79%
Royalty Pharma PLC5.73%
Amgen Inc5.19%
Vertex Pharmaceuticals Inc4.93%
Illumina Inc4.67%
Natera Inc4.50%
Vericel Corp3.85%
Moderna Inc3.58%

PBE top ten by weight, 49.9% of the fund, of its 31 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 31 stocks in biotech, 34% of its weight in S&P 500 companies · First traded Jun 23, 2005 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, PBE Fact Sheet: Invesco Biotechnology & Genome ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/pbe/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/pbe.